High SLC20A1 Expression Is Associated With Poor Prognoses in Claudin-low and Basal-like Breast Cancers

• Published in: Anticancer research Vol. 41; no. 1; pp. 43 - 54
• Main Authors: Onaga, Chotaro, Tamori, Shoma, Motomura, Hitomi, Ozaki, Ayaka, Matsuda, Chika, Matsuoka, Izumi, Fujita, Takuma, Nozaki, Yuka, Hara, Yasushi, Kawano, Yohei, Harada, Yohsuke, Sato, Tsugumichi, Mano, Yasunari, Sato, Keiko, Akimoto, Kazunori
• Format: Journal Article
• Language: English
• Published: Greece International Institute of Anticancer Research 01.01.2021
• Subjects: Biomarkers, Tumor; Breast cancer; Breast Neoplasms - genetics; Breast Neoplasms - mortality; Breast Neoplasms - pathology; Breast Neoplasms - therapy; Cell Line, Tumor; Cell viability; Claudins - genetics; Claudins - metabolism; Clinical outcomes; Combined Modality Therapy - methods; Computational Biology - methods; Female; Gene Expression; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Kaplan-Meier Estimate; Markers; Neoplasms, Basal Cell - genetics; Neoplasms, Basal Cell - mortality; Neoplasms, Basal Cell - pathology; Prognosis; Proportional Hazards Models; Radiation therapy; siRNA; Sodium-Phosphate Cotransporter Proteins, Type III - genetics; Sodium-Phosphate Cotransporter Proteins, Type III - metabolism; Therapeutic targets; Tumors; basal-like; prognostic marker; cancer stem cell; ALDH1; SLC20A1; claudin-low; Breast cancer
• ISSN: 0250-7005; 1791-7530
• DOI: 10.21873/anticanres.14750

SLC20A1 has been identified as a prognostic marker in ER+ breast cancer. However, the role of SLC20A1 expression in breast cancer subtypes other than the ER+ types remains unclear. Genomics datasets were downloaded and analyzed, and the effect of SLC20A1 knockdown using targeted siRNA on cell viability and tumor-sphere formation was assessed. SLC20A1 patients with ER+, claudin-low or basal-like breast cancers showed poor prognoses. SLC20A1 patients treated with radiotherapy had poor clinical outcomes. SLC20A1 knockdown suppressed the viability of MDA-MB 231 (claudin-low), MDA-MB 468 (basal-like) and MCF-7 (ER+) cells, and tumor-sphere formation by ALDH1 cells. These results suggest that SLC20A1 is involved in cancer progression and contributes to clinical outcomes in patients with ER+, claudin-low and basal-like breast cancers. SLC20A1 is a potential prognostic marker and therapeutic target in ER+, claudin-low and basal-like breast cancers.